Login to Your Account



Other News To Note


Thursday, April 21, 2011
NanoBio Corp., of Ann Arbor, Mich., announced a licensing agreement with the University of Michigan that provides NanoBio with rights to an antigen that has been shown to prevent urinary tract infections (UTIs) by eliminating E. coli bacteria in the urinary tract following intranasal vaccination. NanoBio said it plans to pair the UTI antigen with the company's nanoemulsion-based NanoStat adjuvant technology as the intranasal delivery mechanism for the vaccine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription